Skip to main content

Table 1 Baseline demographics of the treatment group

From: Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry

Gender (n = 170) Female 74 (44%)
Male 96 (56%)
Age (Median [IQR]) 65.5 [56.0–73.0]
Race (n = 170) American Indian or Alaska Native 0 (0%)
Asian 3 (2%)
Black or African American 16 (9%)
Native Hawaiian or Pacific Islander 1 (1%)
White or Caucasian 140 (82%)
Unknown 7 (4%)
Other 3 (2%)
Ethnicity (n = 170) Hispanic or Latino 19 (11%)
Non-Hispanic 137 (81%)
Unknown 14 (8%)
Other 0 (0%)
Enrollment Year (n = 170) 2015 7 (4%)
2016 37 (22%)
2017 68 (40%)
2018 26 (15%)
2019 23 (14%)
2020 9 (5%)
ECOG (n = 164) 0 78 (48%)
1 61 (37%)
2 or more 25 (15%)
Grade (n = 81) Well Differentiated 57 (70%)
Moderately Differentiated 12 (15%)
Poorly Differentiated 12 (15%)
Tumor Site (n = 152) Foregut 39 (26%)
Midgut 54 (36%)
Pancreas 36 (24%)
Hindgut 10 (7%)
Unknown 13 (9%)
Tumor Burden % (Median [IQR]) 25.9 [11.9–49.8]
Tumor Location (n = 165) Bilobar 77 (47%)
Unilobar 88 (53%)
Extrahepatic Metastasis (n = 161)
Yes (n = 77, 48%) Lung 22 (29%)
Lymph Nodes 22 (29%)
Bone 14 (18%)
Peritoneum 9 (12%)
Small Bowel 6 (8%)
Brain 1 (1%)
Gastric 1 (1%)
Large Bowel 1 (1%)
Prostate 1 (1%)
Uterus 1 (1%)
Other 28 (36%)
No (n = 85, 52%)
Hepatic Resection Yes 23 (14%)
Systemic Therapy (n = 144) Octreotide 119 (83%)
Biologic 49 (34%)
Cytotoxic 58 (40%)
Arterial Embolization (n = 166) Yes 62 (37%)
No 104 (63%)
Biliary Intervention (n = 15) Metallic Stent 2 (13%)
Plastic Stent 1 (7%)
Percutaneous Biliary Drainage 1 (7%)
Surgical Anastomosis 5 (31%)
Other 7 (47%)
Ascites 10 (6%)
Baseline Laboratories Bilirubin in mg/dL (Median [IQR]) 0.9 [0.6–1.4]
Albumin in g/dL (Median [IQR]) 4.1 [3.8–4.3]
ALT in u/L (Median [IQR]) 42.0 [23.8–73.0]
AST in u/L (Median [IQR]) 52.0 [28.0–72.0]
INR Ratio (Median [IQR]) 1.1 [1.0–1.3]
Creatinine in mg/dL (Median [IQR]) 1.1 [0.9–1.4]
Chromogranin A in ng/mL (Median [IQR]) 543 [215–2981]
Platelet Count in thousands/uL (Median [IQR]) 239.5 [170.5–315.8]
  1. IQR interquartile range